



# SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: January 27, 2022

To,

The Corporate Services Department, Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	Manager - Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	--

Dear Sir/Madam,

**Subject: Certificate pursuant to Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021**

With reference to the subject captioned above, please find enclosed herewith the Quarterly Reconciliation of Share Capital Audit Report pursuant to regulation 76 of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31, 2021.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh  
Company Secretary & Compliance Officer  
Membership No.: A44973



**Corporate Office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063. Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011

CIN: U51900MH2008PLC180452 | E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) | Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory**

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.- Khed, Dist.- Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**

# Mahesh M. Darji

Practicing Company Secretary  
B.Com., DBM, LLB, FCS

To,  
The Board of Directors,  
**Supriya Lifescience Limited**  
**MUMBAI**

**SUB: Reconciliation of Share Capital Audit Certificate in terms of Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018**

Dear Sirs,

I have examined the Register of Members, Beneficiary details furnished by the depositories and other records/ documents maintained by **Supriya Lifescience Limited** (hereinafter referred to as "the Company") and **Link Intime India Private Limited** the Registrar and Transfer Agent of the Company, for issuing of this certificate in accordance with Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018.

In my opinion and to the best of my information and according to the explanations given to me and based on such verification as considered necessary, I hereby certify that:

1	For Quarter Ended	<b>31.12.2021</b>	
2	ISIN	INE07RO01027	
3	Face Value	Equity Shares of Rs. 2/- each	
4	Name of the Company	<b>Supriya Lifescience Limited</b>	
5	Registered Office Address	207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063	
6	Correspondence Address	As above	
7	Telephone & Fax Nos.	Tel. No. +91 22 40332727; Fax No: +91 22 26860011	
8	Email Address	<a href="mailto:cs@supriyalifescience.com">cs@supriyalifescience.com</a>	
9	Names of the Stock Exchanges where the Company's securities are listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)	
		<b>Number of Shares</b>	<b>% of Total Issued Capital</b>
10	Issued Capital	80482800	
11	Listed Capital (Exchange-wise) (as per company records)	BSE	80482800
		NSE	80482800
12	Held in dematerialized form in CDSL	61871605	76.88
13	Held in dematerialized form in NSDL	18611195	23.12
14	Physical	0	0
15	Total No. of shares (12+13+14)	<b>80482800</b>	<b>100.00</b>



# Mahesh M. Darji

Practicing Company Secretary  
B.Com., DBM, LLB, FCS

16	Reasons for difference if any, between (10&11), (10&15), (11&15)	N.A				
17	Certifying the Details of changes in share capital during the quarter under consideration as per Table Below:					
Particulars ***	No. of Shares	Applied/ Not Applied For Listing	Listed on Stock Exchanges (Specify Names)	Whether Intimated to CDSL	Whether Intimated to NSDL	In-principal Approval Pending for SE (Specify Names)
Allotment Under Initial Public Offering	72,99,270	Applied and Received Listing final Listing Approval from BSE on December 28, 2021 and from NSE on December 28, 2021	BSE and NSE	Yes	Yes	Not Applicable
*** Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify).						
18	Register of Members is updated (Yes/No) If not, updated up to which date.					Yes
19	Reference of previous quarter with regard to excess dematerialised shares, if any.					Nil
20	Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?					N.A.
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 30 days with the reasons for delay					
Total No. of Demat Request			No. of Request	No. of Shares	Reasons for Delay	
Confirmed after 21 Days (from the date of receipt of DRF by RTA)			---	---	---	
Pending for more than 21 days (from the date of receipt of DRF by RTA)			---	---	---	
22	Name, Telephone & Fax No. of the Compliance Officer of the Company		<b>Shweta Singh</b> 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063 Tel. No. +91 22 40332727; Email: <a href="mailto:cs@supriyalifescience.com">cs@supriyalifescience.com</a>			



27/01/22

# Mahesh M. Darji

Practicing Company Secretary  
B.Com., DBM, LLB, FCS

23	Name, Address, Tel. & Fax No., Registration no. of the Auditor	<b>Mahesh Darji (C.S.)</b> FCS - 7175 C.P. - 7809 211, Building No. 1, Sona Udyog, Parsi Panchayat Road, Andheri (E), Mumbai - 400 069. Email: mahesh@ngshah.com Tel. 022 - 2820 3581 Tel. 022 - 2820 3582
24	Appointment of common agency for share registry work If yes (name & address)	<b>Link Intime India Private Limited</b> C-101, 1 <sup>st</sup> Floor, 247 Park, Lal Bahadur Shastri Marg, Vikroli (West), Mumbai - 400 083.
25	Any other details that the auditor may like to provide. (E.g. BIFR company, delisting from SE, company changed its name etc.)	
	It may be noted that the Company has floated Initial Public Offer (IPO) for total of Rs. 700 Crores wherein Rs. 200 Crores was through Fresh Issue and Rs. 500 Crores was through Offer For Sale. The Company has allotted fresh 72,99,270 Equity Shares under IPO during the quarter under reference. The Equity Shares of the Company are listed on BSE and NSE. The Company has listed final listing approval during the quarter ended December 31, 2021 on December 28, 2021 from BSE and on December 28, 2021 from NSE.	

**Note:** Due to COVID-19 outbreak and Lockdown situation, this Certificate has been issued relying on the certificate, information, details, data, documents and explanation provided by the Company and its officers, agents and authorized representatives and Registrar and Transfer Agent in electronic form, without physically verifying at their office.

Place: Mumbai

Date: 27.01.2022

UDIN: F007175C002301412



(MAHESH M. DARJI)  
Company Secretary  
C.P. No: 7809